Summarized by Masters of Longevity from Longevity Technology.
A preview of a preclinical research article on a brain‑penetrant small‑molecule targeting lysosomal pathways for neurodegeneration, explaining its experimental focus and potential therapeutic relevance.
Key Takeaways
- LW-1017 activated TRPML1 with nanomolar potency and induced nuclear translocation of TFEB, TFE3 and MiTF.
- Oral dosing produced robust brain exposure and sustained modulation of autophagy–lysosomal biomarkers in preclinical tests.
- LW-1017 reduced alpha-synuclein and preserved dopaminergic neurons in Parkinson’s models and lowered amyloid and tau in Alzheimer’s models.
